GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (FRA:5Y6) » Definitions » YoY EBITDA Growth

Compass Pathways (FRA:5Y6) YoY EBITDA Growth : 12.15% (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Compass Pathways YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Compass Pathways's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was 12.15%.

Compass Pathways's EBITDA per Share for the three months ended in Jun. 2024 was €-0.50.


Compass Pathways YoY EBITDA Growth Historical Data

The historical data trend for Compass Pathways's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Pathways YoY EBITDA Growth Chart

Compass Pathways Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial -42.16 -198.56 30.59 -27.87 -2.58

Compass Pathways Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.51 -40.37 32.75 7.81 12.15

Compass Pathways YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Compass Pathways's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-2.071--2.019)/ | -2.019 |
=-2.58 %

Compass Pathways's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (Q: Jun. 2024 )
=(EBITDA per Share (Q: Jun. 2024 )-EBITDA per Share (Q: Jun. 2023 )) / | EBITDA per Share (Q: Jun. 2023 )) |
=(-0.499--0.568)/ | -0.568 |
=12.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Compass Pathways YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Compass Pathways's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Compass Pathways Business Description

Traded in Other Exchanges
Address
33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Compass Pathways Headlines

No Headlines